Nifty Healthcare Index News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Nifty Healthcare Index from all sources in a single place.

Load latest

Zydus Lifesciences Ltd.

11 Apr 2025

859.65

-2.34%

Company Update

Zydus Lifesciences Ltd - 532321 - Incorporation Of A Wholly Owned Subsidiary In France

BSE India

Incorporation of a wholly owned subsidiary in France

pdf

Aurobindo Pharma Ltd.

11 Apr 2025

1220.10

-3.00%

Aurobindo Pharma's US Plant Gets 11 FDA Observations

NDTV Profit

The inspection took place from March 24 to April 10, 2025.

Aurobindo Pharma Ltd. is trading below its 150 day SMA of 1260.2

Mankind Pharma Ltd.

11 Apr 2025

2557.50

-1.60%

Corp. Note

Mankind Pharma Ltd - 543904 - Compliances-Half Yearly Report (SEBI Circular No. CIR/IMD/DF-1/67/2017)

BSE India

Disclosure pursuant to Paragraph 9.1 (a) of the Chapter VIII of SEBI Master Circular No. SEBI/HO/DDHS/PoD1/P/CIR/2024/54 dated May 22, 2024.

pdf

Sun Pharmaceutical Industries Ltd.

11 Apr 2025

1787.40

-0.91%

Sun Pharma stock up 2.4% as roads cleared for launch of alopecia drug

Business Standard

According to market estimates, Leqselvi is projected to contribute $90 million to Sun Pharma's sales in FY26, and $125 million in FY27

Sun Pharmaceutical Industries Ltd. is trading above all available SMAs

Here's why Sun Pharma share price advanced 5% in trade on April 11; details

Business Standard | 11 Apr 2025

Apollo Hospitals Enterprise Ltd.

11 Apr 2025

6953.00

-2.88%

Apollo Hospitals Planning Buyouts To Boost North India Footprint

NDTV Profit

Apollo will add about 3,500 beds over three to four years, with focus mainly on India's northern region.

Apollo Hospitals Ent.. has an average target of 7471.80 from 5 brokers.

Laurus Labs Ltd.

11 Apr 2025

625.65

-3.08%

Laurus Labs surges 8%, stock records sharpest intraday gain since Jan 30

Business Standard

The pipeline is expected to be robust, and the company expects to do well in the human health and animal health CDMO divisions in Q4FY25E and in FY26E, according to analysts.

Laurus Labs Ltd. has gained 39.87% in the last 6 Months

Biocon Ltd.

11 Apr 2025

311.85

-4.56%

Biocon shares jump 5.5% as USFDA clears biosimilar Cancer drug JOBEVNE

livemint

Biocon's share price rose 5.5% after USFDA approved JOBEVNE, a biosimilar cancer drug. This marks the company's seventh USFDA-approved biosimilar and enhances its oncology portfolio, increasing investor confidence and market optimism.

Biocon Ltd. is trading below all available SMAs

Biocon subsidiary gets USFDA nod for Everolimus tablets; share zooms 6%

Business Standard | 11 Apr 2025 1 more

Aurobindo Pharma Ltd.

11 Apr 2025

1220.10

-3.00%

Company Update

Aurobindo Pharma Ltd - 524804 - Completion Of US FDA Inspection At Raleigh Plant, North Carolina, …

BSE India

Intimation of completion of US FDA inspection at Raleigh Plant, North Carolina, owned by Aurolife Pharma LLC, a wholly owned stepdown subsidiary of the Company.

pdf

Cipla Ltd.

11 Apr 2025

1525.90

-1.66%

Cipla gets USFDA nod to market generic version of cancer drug Abraxane

Business Standard

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the US Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for paclitaxel protein-bound particles for injectable suspension (albumin-bound), 100 mg/vial, single-dose vial, Cipla said in a regulatory filing. Cipla's protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for injectable suspension 100 mg/vial. Protein-bound paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas. The product is expected to be launched in the first half of the current fiscal year in the US, the Mumbai-based drugmaker said. Shares of the company were trading 2.73 per cent up at Rs 1,454.90 apiece on the BSE.